
|Articles|May 12, 2004
Neoadjuvant chemo affects PSA levels post-RP, but histology is unchanged
Weekly neoadjuvant chemotherapy with docetaxel (Taxotere) achieved aPSA response in almost 80% of a small group of high-risk prostate cancerpatients enrolled in a feasibility study of single-agent therapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











